Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of IDRX-42 in metastatic or unresectable gastrointestinal stromal tumors
jRCT2051240255Phase 1Active, not recruiting
- Sponsor
- IDRx
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of IDRX-42 in gastrointestinal stromal tumor (GIST), sponsored by IDRx. Primary endpoints: Treatment-emergent adverse events and laboratory safety and Objective response rate. Started Mar 2025; status: active, not recruiting.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2051240255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240255.